Enovis Corporation $ENOV Shares Purchased by LPL Financial LLC

LPL Financial LLC raised its stake in Enovis Corporation (NYSE:ENOV) by 40.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,949 shares of the company’s stock after buying an additional 14,013 shares during the quarter. LPL Financial LLC’s holdings in Enovis were worth $1,870,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its position in Enovis by 266.7% in the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock valued at $27,000 after buying an additional 536 shares during the last quarter. Quarry LP lifted its position in Enovis by 506.1% in the fourth quarter. Quarry LP now owns 897 shares of the company’s stock valued at $39,000 after buying an additional 749 shares during the last quarter. GAMMA Investing LLC lifted its position in Enovis by 144.8% in the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock valued at $45,000 after buying an additional 692 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in Enovis by 57.7% in the first quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company’s stock valued at $74,000 after buying an additional 725 shares during the last quarter. Finally, McIlrath & Eck LLC acquired a new position in Enovis in the fourth quarter valued at about $152,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Down 1.5%

ENOV stock opened at $29.9940 on Thursday. The company’s 50 day moving average price is $30.13 and its 200 day moving average price is $34.31. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25. Enovis Corporation has a fifty-two week low of $25.47 and a fifty-two week high of $49.83. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -2.10 and a beta of 1.70.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, August 7th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The firm had revenue of $564.50 million for the quarter, compared to analyst estimates of $555.80 million. During the same period in the prior year, the firm earned $0.62 earnings per share. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. On average, equities research analysts anticipate that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Insider Buying and Selling at Enovis

In other news, CFO Phillip Benjamin (Ben) Berry bought 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were purchased at an average cost of $29.71 per share, for a total transaction of $74,275.00. Following the completion of the purchase, the chief financial officer owned 116,729 shares of the company’s stock, valued at approximately $3,468,018.59. This represents a 2.19% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.70% of the company’s stock.

Wall Street Analyst Weigh In

ENOV has been the topic of a number of recent analyst reports. Evercore ISI decreased their target price on shares of Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Canaccord Genuity Group cut their price target on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. JMP Securities cut their price target on shares of Enovis from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Friday, May 9th. Needham & Company LLC cut their price target on shares of Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Finally, Wells Fargo & Company cut their price target on shares of Enovis from $48.00 to $41.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $51.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.